NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

NVAX

Novavax, Inc. Common Stock Nasdaq Global Select
$171.5
Open: $171.74 High: $176.88 Low: $152.57 Close: $171.49
Range: 2021-05-06 - 2021-05-07
Volume: 6,195,103
Market: Closed
Powered by Finage Stock APIDelayed data
NVAX
Novavax, Inc. Common Stock 20 Firstfield Road Gaithersburg MD, 20878 http://www.novavax.com
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
  • CEO: Stanley Charles Erck
  • Employees: 347
  • Sector: Healthcare
  • Industry: Biotechnology
NVAX News
Latest news about the NVAX
  • Should Novavax Be Worried About Losing IP Rights?

    On Wednesday, President Joe Biden announced that his administration supported the waiver of intellectual property (IP) rights for COVID-19 vaccines in negotiations at the World Trade Organization (WTO). Is this a danger for Novavax (NASDAQ: NVAX) investors? One important point is that Biden's announcement is not a law or a verdict in a patent case.

    View More →
  • U.S. backing waiver of patent protection for vaccines is a ‘complex issue’: Doctor

    Dr. Payal Patel, Infectious Diseases Physician, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.

    View More →
  • Elizabeth Warren responds to Biden's backing of COVID-19 vaccine patent waivers: 'I'm delighted'

    On Wednesday, the Biden administration backed waiving intellectual property protections for COVID-19 vaccines, a move that delighted Sen. Elizabeth Warren.

    View More →
  • Moderna and Other Covid-19 Vaccine Stocks Are Sliding. The Reaction Might Be Overblown.

    Moderna, Novavax, BioNTech, and others have shed billions in market valuation, but it’s far from clear how soon an intellectual property waiver could actually affect Covid-19 vaccine sales, if at all.

    View More →
  • Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture and distribute 350 million doses of NVX-CoV2373 to countries participating under the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. Under a separate purchase agreement with Gavi, the Serum Institute of India (Serum Institute) is expected to manufacture and deliver the balance of the 1.1 billion doses of Novavax' vaccine.

    View More →
  • UPDATE 2-Novavax to start shipping COVID-19 vaccines to COVAX program in third quarter

    Novavax Inc said on Thursday it has agreed to start shipping doses of its COVID-19 vaccine candidate to the COVAX program in the third quarter of 2021 in an effort to deliver on its promise to provide 1.1 billion shots to the global vaccination program. Novavax said it will manufacture and ship 350 million shots itself. India's Serum Institute (SII) will provide the remainder of the 1.1 billion shots to COVAX through a separate agreement.

    View More →
  • UPDATE 1-Novavax vaccine shows 51% efficacy against South African variant, study finds

    Novavax Inc's COVID-19 vaccine had efficacy of 51% against infections caused by the South African variant among people who were HIV negative, and 43% in a group that included people who were HIV positive, according to a new analysis published on Wednesday. The variant, known as B.1.351, carries mutations that threaten the efficacy of COVID-19 vaccines, several studies have shown. Most vaccine makers, including Novavax, are testing versions of their vaccines to protect against emerging variants.

    View More →
  • Moderna Stock Dives As Biden Considers Waiving Covid Vaccine Patents

    Moderna stock crashed late Wednesday on reports President Joe Biden will support waiving the patent rights covering Covid vaccines. Other vaccine makers saw their stocks fall on the news.

    View More →
  • Moderna releases new information on booster shots

    Yahoo Finance's Anjalee Khemlani provides the latest update on Moderna's booster shot studies.

    View More →
  • New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the initial primary analysis of a Phase 2b clinical trial conducted in South Africa of its NVX-CoV2373 COVID-19 vaccine candidate in the New England Journal of Medicine (NEJM). The published data provide additional detail of an initial analysis conducted in January, while more robust data from a complete analysis of the study was subsequently shared in March 2021. The data on the initial analysis will be published online ahead of print in NEJM's May 6, 2021 issue.

    View More →
  • Novavax vaccine shows 43% efficacy against South African variant, study finds

    Novavax Inc's COVID-19 vaccine had efficacy of 43% against infections caused by the South African variant in a group that included people with and without HIV, and 51% in people who were HIV negative, according to a new analysis published on Wednesday. The post-hoc analysis was published in the New England Journal of Medicine along with full data from the company's trial in South Africa, which included nearly 2,700 volunteers who had not been previously infected with the coronavirus. Results announced in January showed efficacy of 49.4% against symptomatic COVID-19 in the South African trial looking at a mixture of the original virus and the South African variant, and 60.1% among those who were HIV-negative.

    View More →
  • Former Acting CDC Director on why it's 'really important' to pay attention to COVID-19 variants

    Dr. Richard Besser, Former Acting CDC Director, Robert Wood Johnson Foundation President & CEO, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.

    View More →
  • Investing in the Covid-19 vaccine companies? Here’s the great divide in the group

    Moderna (MRNA) and BioNTech (BNTX) — do look pricey. One big problem for all of us is that widespread use of vaccines is concentrated in the developed world. “There is evidence that some variants have the capability to evolve to evade the vaccines,” says Slaughter.

    View More →
  • Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?

    Oxford Vaccine Group, the original developer of the COVID-19 vaccine marketed by AstraZeneca (NASDAQ: AZN), recently announced that it's conducting a clinical study evaluating multiple COVID-19 vaccines. In this Motley Fool Live video recorded on April 21, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have anything to worry about from this study. Keith Speights: Now in some other news, Brian, Oxford Vaccine Group in the U.K. is conducting what they're calling a mix-and-match clinical study of several COVID-19 vaccines.

    View More →
  • Is Novavax Stock A Buy On Hints Its Covid Vaccine Is Nearing Authorization?

    Novavax said in March its coronavirus vaccine was 96.4% effective in a Phase 3 test. It's also effective against variants. It's now seeking authorization. Is NVAX stock a buy?

    View More →
  • Should You Buy Novavax Before Its Earnings Report?

    Novavax (NASDAQ: NVAX) is inching closer to its goal: the commercialization of its coronavirus vaccine candidate. Now, the question is whether it's a good idea to scoop up Novavax shares ahead of the upcoming earnings report. Novavax has reached a crucial moment.

    View More →
  • Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

    Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

    View More →
  • Biden aims to have 70% of U.S. adults receive first vaccine shot by July 4th

    Yahoo Finance’s Jessica Smith reports the latest details on Biden’s pandemic recovery goals.

    View More →
  • Why Shares of Novavax Rose 31% Last Month

    Novavax (NASDAQ: NVAX) had a busy month in April. Shares gained 30% according to S&P Global Market Intelligence. Early in the month, the stock began climbing after Johnson & Johnson's vaccine was temporarily halted.

    View More →
  • These 2 Once-Hot Stocks Sent the Nasdaq Lower Monday

    Wall Street in general got off to a good start on the first trading day of May. However, the Nasdaq Composite (NASDAQINDEX: ^IXIC) was the sole laggard among the big indexes, falling about a third of a percent as of 2:30 p.m. EDT Monday afternoon even as other major benchmarks climbed to record heights. A couple of stocks played noteworthy roles in dragging down the Nasdaq on Monday. Biopharmaceutical company Novavax (NASDAQ: NVAX) got some bad news on its COVID-19 vaccine, while Tesla (NASDAQ: TSLA) appears to be suffering a delay that could put a wrench in its plans to boost electric vehicle (EV) production in the near future.

    View More →